MedTrace Logo

Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

NCT06655090 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2024-10-23

No results posted yet for this study

Summary

This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development, progression and prognosis of pulmonary fibrosis; 2) systematically evaluate the safety and effectiveness of frozen lung biopsy, surgical lung biopsy/thoracoscopic lung biopsy and other techniques, and to optimize the histological diagnosis method of f-ILD; 3) construct a set of artificial intelligence (AI) evaluation system for quantitative evaluation of pulmonary fibrosis and its severity, and develop application software; 4) excavate and verify important molecular targets for the formation of pulmonary fibrosis and identify biomarkers; 5) combined with clinical phenotype, imaging, pathology and biomarkers to establish f-ILD early recognition and progress model, intervention strategies, guidelines and consensus, and applicated nationwide.

Conditions

  • Interstitial Lung Disease (ILD)

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Nankai University

    collaborator OTHER

  • Jilin University

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Shanghai Chest Hospital

    collaborator OTHER

  • Institute of Basic Medical Sciences CAMS

    collaborator UNKNOWN

  • Tongji Hospital

    collaborator OTHER

  • National Institute for Occupational Health and Poison Control

    collaborator UNKNOWN

  • Infervision Medical Technology Company Limited

    collaborator UNKNOWN

  • Dai Huaping

    lead OTHER

Principal Investigators

  • Huaping Dai, M.D. Ph.D. · China-Japan Friendship Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2024-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06655090 on ClinicalTrials.gov